Compare GPMT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPMT | IFRX |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | United States | Germany |
| Employees | 28 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 66.0M |
| IPO Year | N/A | 2017 |
| Metric | GPMT | IFRX |
|---|---|---|
| Price | $1.48 | $2.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $6.25 |
| AVG Volume (30 Days) | 144.4K | ★ 3.0M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $458.85 | N/A |
| Revenue Next Year | $8.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.24 | $0.74 |
| 52 Week High | $3.12 | $2.95 |
| Indicator | GPMT | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 54.72 | 56.28 |
| Support Level | $1.24 | $0.96 |
| Resistance Level | $1.58 | $2.95 |
| Average True Range (ATR) | 0.07 | 0.22 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 78.26 | 20.86 |
Granite Point Mortgage Trust Inc focuses on directly originating, investing in, and managing senior floating rate commercial mortgage loans and other debt and debt-like commercial real estate investments. The company constructs its investment portfolio on a loan-by-loan basis, emphasizing rigorous credit underwriting, selectivity, and diversification, and assesses each investment from a fundamental value perspective relative to other opportunities available in the market. It typically provides intermediate-term bridge or transitional financing for a variety of purposes, including acquisitions, recapitalizations, refinancing, and a range of business plans, including lease-up, renovation, repositioning and repurposing of the commercial property.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.